Liquidia Corporation (LQDA)

Environment story

Liquidia is a biopharmaceutical company with no disclosed Scope 1, Scope 2, or Scope 3 emissions reporting, net-zero targets, or environmental sustainability initiatives. The company manufactures pharmaceutical products (YUTREPIA, treprostinil formulations) through third-party contract manufacturers (Lonza, LGM) but provides no quantitative environmental impact disclosure. No environmental controversies, resource-extraction controversies, or sustainability commitments are mentioned in the 10-K. The company operates manufacturing facilities in Morrisville, North Carolina and engages in research and development activities but discloses no carbon footprint, renewable energy usage, waste management practices, or climate risk mitigation strategies. Absence of material environmental risk disclosure or ESG commitment is notable for a company generating over $148 million in product revenue.

Social story

Liquidia discloses minimal social metrics. No CEO-to-median-worker pay ratio is disclosed. No documented union-suppression activities or major strikes are reported in the 10-K. Leadership diversity metrics are not provided; board composition and diversity percentages are undisclosed. No supply-chain human-rights audits or labor practices reporting is evident. The company notes dependence on 'skilled labor' and acknowledges competition for 'research, technical, clinical and sales and marketing personnel' but provides no workforce diversity, turnover, safety, or labor-relations data. No diversity initiatives, supplier diversity programs, or labor-relations commitments are disclosed. Absence of material social-responsibility disclosure suggests limited formalized social governance for a company with over 200 employees (implied by commercial field force and R&D operations).

Governance story

Liquidia's governance structure includes material litigation risk and regulatory dependency. The company faces multiple patent-infringement lawsuits from United Therapeutics (three patent-litigation cases and two trade-secret misappropriation suits) alleging YUTREPIA infringement of U.S. Patents '327, '782, and '723887, with United Therapeutics seeking injunctive relief to remove YUTREPIA from market or restrict indications. A June 2025 trial in '327 Patent Litigation yielded uncertain outcome; preliminary injunction motion denied May 2025 in '782 litigation; trade-secret claims survived summary judgment denial. Board independence, share structure, and lobbying spend are undisclosed. The HCR debt facility ($175 million funded, $25 million remaining available) contains restrictive operating covenants, minimum cash requirements ($15.0 million), and broad asset collateralization that constrains financial and strategic flexibility. No evidence of antitrust, consumer-safety fines, or SEC consent decrees is disclosed. Governance risk is elevated due to patent-litigation uncertainty and debt covenant restrictions.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Liquidia Corporation. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Liquidia Corporation in the app for interactive charts and portfolio building.

More in Healthcare